Navigation Links
OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5
Date:4/28/2011

ling pathway.  Bayer has the option to license OncoMed's biologics in the Wnt pathway at any point through the completion of Phase 1 studies.  In addition, Bayer and OncoMed are working together to discover small molecule Wnt signaling inhibitors as part of the collaboration.

About Cancer Stem Cells

Cancer stem cells, a small, resilient subset of cells found in tumors, have the capacity to self-renew and differentiate, leading to tumor initiation and driving tumor growth, recurrence and metastasis.  Also referred to as "tumor-initiating cells," these cells were first discovered by OncoMed's scientific founders in breast cancer and have subsequently been identified in many other types of solid tumor cancers, including cancer of head and neck, lung, prostate, pancreas and glioblastoma.  Cancer stem cells appear to be preferentially resistant to both standard chemotherapy and radiotherapy.  OncoMed's strategy is to improve cancer treatment by specifically targeting the key biologic pathways which are thought to be critical to the activity and survival of cancer stem cells.  OncoMed's novel therapeutics target cancer stem cell proteins and have the potential to be developed against a range of tumor types.  

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastasis.  A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers.  OncoMed has advanced three anti-cancer stem cell monoclonal antibodies into the clinic, OMP-21M18, OMP-59R5 and OMP-18R5, which target key cancer stem cell signaling pathways including Notch and Wnt.  In addition, OncoMed's pipe
'/>"/>

SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
2. SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies
3. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
4. OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million
5. OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5
6. OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 Investor-Edge ... Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 16, 2014, ended on a mixed ...
(Date:10/17/2014)... 17, 2014  UBM Medica US announces that ... and other clinicians who treat patients with type ... effective use of insulin .  Nearly ... replacement therapy – daily injections of one or ... in the function of pancreatic beta cells. Insulin is ...
(Date:10/17/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" ... biopharmaceutical company in China , ... from the China Food and Drug Administration (the ... concentrate ("PCC") at its Shandong Taibang facility. The ... facility for Good Manufacturing Practices ("GMP") compliance in ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... Incorporated,(Nasdaq: VPHM ) today announced that Michel de ... at the Acumen BioFin Rodman &,Renshaw 9th Annual Healthcare ... The conference is being held at the New York ... investors through, http://www.viropharma.com and available through November 20, ...
... Research,Associates, LLC announced today that it has ... Corporation (Amex: CVM ). The,full 56-page ... . CEL-SCI Corporation develops immune-based cancer ... is Multikine(R), a,next-generation, comprehensive immunotherapy that targets ...
Cached Medicine Technology:Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation 3
(Date:10/20/2014)... 2014 Allegheny General Hospital’s (AGH) Cardiovascular ... physicians to repair a damaged mitral valve as the ... system, developed by Abbott Vascular , is designed ... life-threatening condition in which the heart’s mitral valve leaflets ... from the heart’s left ventricle into the left atrium. ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, 2014 and ... AAP, http://www.ohioaap.org ) is joining the National Highway Traffic ... talk to their teens and always set the rules before ... leading cause of death for U.S. teens. In 2012, there ... (42%) of those teen drivers were killed in crashes. While ...
(Date:10/20/2014)... 20, 2014 Houston plastic surgeon ... key elements of his innovative True Form Tummy ... surgery residents and faculty at The University of ... too, was once a medical student. Patronella, who is ... cosmetic plastic surgery practices in Texas, The Aesthetic ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... TeamPraxis, Hawaii,s premier physician management service organization (MSO) that ... Hawaii physicians, capped off its inaugural year of selling ... with seven new large client signings, bringing the first-year ... , , These sales completed a very successful ...
... ... , ... 2009 -- Talyst , a leader in pharmacy automation systems, found June to be ... was awarded as one of "Washington,s 100 Best Companies to Work For 2009" by Seattle ...
... MEDai, Inc. and Gold Standard, Inc., two Elsevier companies, ... medication therapy management (MTM) system that enables health plans, benefit ... Program requirements for 2010 and beyond for their Medicare Part ... to reporting and outcomes measurement. MTM 360 ...
... ... last year, blue sky scrubs has added new products and features, updated their content and ... ... has released a new version of their website, http://www.blueskyscrubs.com . Some of the ...
... ... for their HEPA-CARE® Air Filtration Systems and Germicidal UV Modules from healthcare facilities ... ... 2009 -- Abatement Technologies®, Inc. sees strong demand for their HEPA-CARE® Air Filtration ...
... Jesse ... delighted to announce ONRAD,s new web based PACS Application Service Provider (ASP) model. , ... Riverside, CA (PRWEB) July 9, 2009 ... (ONRAD) is delighted to announce ONRAD,s new web based PACS Application Service Provider (ASP) model. ...
Cached Medicine News:Health News:TeamPraxis Finishes Strong First Year of National Sales 2Health News:TeamPraxis Finishes Strong First Year of National Sales 3Health News:TeamPraxis Finishes Strong First Year of National Sales 4Health News:TeamPraxis Finishes Strong First Year of National Sales 5Health News:Talyst Receives Multiple Honors for Workplace Excellence 2Health News:Talyst Receives Multiple Honors for Workplace Excellence 3Health News:To Save Payors Time, Effort and Resources, MEDai and Gold Standard Collaborate on New CMS Medication Therapy Management Initiative 2Health News:To Save Payors Time, Effort and Resources, MEDai and Gold Standard Collaborate on New CMS Medication Therapy Management Initiative 3Health News:To Save Payors Time, Effort and Resources, MEDai and Gold Standard Collaborate on New CMS Medication Therapy Management Initiative 4Health News:Nursing Scrubs and Medical Scrubs Company blue sky scrubs Launches Enhanced Website 2Health News:Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic 2Health News:Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic 3Health News:ONRAD Announces New PACS Application Service Provider Model 2
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Medicine Products: